BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 16, 2026
See today's BioWorld MedTech
Home
» FDA clears Vuno’s AI-based MRI reading software for early Alzheimer’s detection
To read the full story,
subscribe
or
sign in
.
FDA clears Vuno’s AI-based MRI reading software for early Alzheimer’s detection
Oct. 25, 2023
By
Marian (YoonJee) Chu
Vuno Inc. gained a U.S. FDA’s 510(k) clearance for its artificial intelligence (AI)-powered brain quantification device, Vuno Med-Deepbrain, to diagnose possible dementia in patients “even before mild cognitive impairment.”
Medical technology
Regions
Regulatory
Diagnostics
Neurology/psychiatric
U.S.
FDA